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Abstract
Background & Aims—Intestinal metaplasia (IM) and spasmolytic polypeptide-expressing
metaplasia (SPEM) are precursors to gastric carcinogenesis. We sought to identify molecular
biomarkers of gastric metaplasias and gastric cancer by gene expression profiling of metaplastic
lesions from patients.
Methods—cDNA microarray analysis was performed on IM and SPEM cells isolated from
patient samples using laser capture microdissection. Up-regulated transcripts in metaplstic lesions
were confirmed by immunostaining analysis in IM, SPEM, and gastric cancer tissues. Proteins that
were highly expressed specifically in gastric cancer tissues were analyzed for their association
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with survival in a test set (n=450) and a validation set (n=502) of samples from gastric cancer
patients.
Results—Compared to normal chief cells, 858 genes were differentially expressed in IM or
SPEM samples. Immunostaining was detected for 12 proteins, including 3 new markers of IM
(ACE2, LGALS4, AKR1B10) and 3 of SPEM (OLFM4, LYZ, DPCR1). Of 13 proteins expressed in
IM or SPEM, 8 were expressed by 17%–50% of human gastric cancer tissues (MUC13, OLFM4,
CDH17, KRT20, MUC5AC, LGALS4, AKR1B10, REG4). Expression of CDH17 or MUC13
correlated with patient survival in the test and a validation sets. Multivariate analysis showed that
CDH17 was an independent prognostic factor in patients with stage I or node-negative disease.
Conclusion—We identified several novel biomarkers for IM, SPEM, and gastric cancer using
gene expression profiling of human metaplastic lesions. Expression of CDH17 and MUC13 was
upregulated in gastric cancer tissues. CDH17 is a promising prognostic marker for early-stage
gastric cancer.
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Introduction
Although the incidence of gastric cancer has decreased in the western countries, it still ranks
as the fourth most common cancer worldwide and the second most common cause of
cancer-related death.1 While considerable improvements have occurred in early detection,
surgical technique, and adjuvant chemotherapy,2,3 little has been achieved in the
development of novel prognostic markers. For prediction of prognosis, only the TNM
staging system and surgical curability (R-category) are commonly used in the clinical
setting.4 Therefore, novel molecular prognostic markers for gastric cancer, especially those
with insights within the same TNM stage, are needed not only for the accurate prediction of
recurrence, but also for the personalized treatment of each patient. This need is especially
apparent in the treatment of early-stage gastric cancer patients, where adjuvant
chemotherapy could be applied more selectively if effective prognostic markers were
available.
Similar to other malignancies, gene expression profiling using cDNA microarray has been
previously performed on tumor samples to identify new diagnostic and prognostic markers
for gastric cancer.5-9 Unfortunately, these studies have yielded few useful biomarkers for
gastric cancer, likely due to the heterogeneity of the original tumor samples and
contamination by the premalignant metaplastic processes in the surrounding mucosa that
usually served as the “normal” control. To avoid these problems, we have focused on gene
expression profiling of gastric metaplastic lesions from the gastric cancer patients to identify
novel biomarkers affecting the early stage of gastric carcinogenesis.
Intestinal metaplasia (IM) is a well-established precursor in gastric carcinogenesis,
especially of intestinal-type tumors.10 Another metaplastic lesion, designated spasmolytic
polypeptide expressing metaplasia (SPEM), shows morphological similarity with deep antral
gland cells and expresses trefoil factor 2 (TFF2, spasmolytic polypeptide).11,12 In human
studies, SPEM was found in 90% of fundic mucosal samples adjacent to gastric cancer.13,14
Recent investigations in mice support the development of SPEM from transdifferentiation of
normal chief cells into mucous metaplasia following loss of gastric parietal cells.15,16 Also,
evidence from rodents suggests that IM and dysplasia can develop from SPEM.17,18
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In this study, we performed cDNA microarray analysis on mRNA isolated from
microdissected IM, SPEM, and normal chief cell lineages from human stomach. By testing
and validating expression of putative up-regulated proteins in two large cohorts of gastric
cancer tissues, we identified an independent prognostic biomarker, CDH17, in stage I or
node-negative gastric cancer.
Materials and Methods
Oligonucleotide microarray from microdissected RNA
Total RNAs from both IM and SPEM lineages adjacent to intestinal-type gastric cancer in
fundus were collected from 6 patients who underwent gastrectomy. In addition, since
transdifferentiation of chief cells into SPEM appears to be the first step in metaplastic
response to oxyntic atrophy, RNAs from normal chief cells were collected from 6 patients
who underwent gastrectomy with no evidence of atrophic gastritis, IM, SPEM or gastric
cancer in the fundic mucosa. All samples were obtained from Department of Surgery at
Seoul National University Hospital (SNUH) from July 2007 to July 2008. This work was
approved by the institutional review board (IRB) at SNUH and written consents were
obtained from each patient. Detailed information on each patient is shown in Supplementary
Table 1.
Before performing the laser capture microdissection (LCM), double immunohistochemical
staining with anti-human MUC2 (1:200, sc-15334, Santa Cruz, CA) and anti-human TFF2/
SP (1:100, a gift from Dr. Nicholas Wright, Cancer UK, London, UK) as well as
hematoxylin-eosin staining were performed for every tissue sample to confirm the presence
and location of IM and SPEM (Supplementary Fig 1). LCM procedures were performed
using a Veritas Microdissection System (Molecular Devices, CA). Total RNA was extracted
and isolated using a Picopure RNA Isolation Kit (Molecular Devices).
Isolated RNAs were amplified using a NuGEN FFPE amplification kit and labeled using a
NuGEN Ovation™ cDNA Biotin Module V2 kit (San Carlos, CA). RNA quality was
determined using the Agilent 2100 bioanalyzer. Five μg of each sample was hybridized to
Affymetrix U133 Plus 2.0 GeneChip® Expression arrays (∼55,000 probes) according to
manufacturer's instructions. The raw expression data were converted to expression values
using the Affy function in R (http://www.bioconductor.org).
Gene selection
Once expression values were obtained, we filtered those probes/features that had at least
25% samples with intensities above 100 fluorescent units and interquartile range of at least
0.5. The log2-based expression levels were examined using analysis of variance (ANOVA)
and ebayes-moderated t-tests implemented in the limma package; the pair-wise contrasts
tested chief cell versus IM or SPEM. After type I error was mitigated by first testing for the
overall p-value of any difference in means, only those that were found significant in the
overall test underwent pair-wise tests. The significant p-values from the two pair-wise tests
(chief cell versus IM and chief cell versus SPEM) were ranked and a candidate probe list
was compiled, using False Discovery Rate adjusted p-value cut-offs obtained by the linear
step-up method described by Benjamini and Hochberg.19 We used the Annotate package to
convert the probe set definitions to searchable forms that were linked to web-based
databases. We examined pathways associated with these candidate probes using the SPIA
package. The candidate probes associated with known genes were filtered manually for
further analyses of their protein expression. Gene products were prioritized for further
analysis based on their classification as (1) secretory or extracellular protein, (2) protein
with limited expression in stomach and other tissues, or (3) a novel marker in the oncologic
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field. Final selection was based on the availability of antibodies for immunohistochemical
staining in paraffin-embedded tissues.
Tissue microarray (TMA) analysis
To evaluate the protein expression in the normal fundus and metaplastic and cancerous
lesions, two small-scale gastric cancer TMAs were used: (1) a collection of 42 gastric
adenocarcinomas resected at Vanderbilt University Hospital (Vanderbilt-GC; median age:
67 yrs, M:F=24:18,),20 and (2) a collection of 36 gastric adenocarcinomas resected at SNUH
(SNUH-TA78, SuperBioChips, Seoul, Korea; median age: 58 yrs, M:F=27:9,). Another two
large-scale sets of tissue microarrays: (1) a collection of 450 gastric adenocarcinomas
resected at SNUH in 2004 (SNUH-2004-GC, SuperBioChips) as a test set and (2) a
collection of 502 gastric adenocarcinomas resected at SNUH in 1996 (SNUH-1996-GC,
SuperBioChips) as a validation set, were used to evaluate the expression profiles of proteins,
which were expressed in more than 40% of gastric cancers in initial tissue arrays. In both
sets, annotated data for each case were available for age, sex, tumor size and location,
Lauren classification, TNM stage (according to 6th UICC/AJCC TNM classification),
lymphatic invasion, venous invasion, surgical curability, and disease-specific survival period
(Supplementary Table 3). The median follow-up periods were 49.1 months (range: 0.4 ∼
64.4 mo) in SNUH-2004-GC and 76.0 months (range: 2.0 ∼ 96.0 mo) in SNUH-1996-GC,
respectively.
None of the patients received preoperative chemotherapy or radiotherapy. Extended lymph
node dissection was uniformly applied for the curatively resected cases, with mean number
of retrieved lymph nodes of 31.5 (in the test set) and 32.0 (in the validation set),
respectively. Adjuvant chemotherapy was not indicated in patients with stage Ia, but was
usually administered in patients with stage II or higher disease. In patients with stage Ib,
adjuvant chemotherapy was selectively indicated considering patient's physical activity and
the presence of co-morbidity. A 5-fluorouracil (5-FU) based combination (5-FU plus
cisplatin or 5-FU plus mitomycin) was the most commonly used chemotherapeutic regimen.
The analysis of survival data of the patient was approved by the IRB at SNUH.
Immunohistochemical staining
For the immunohistochemistry in human tissues, except SNU-2004-GC and SNU-1996-GC,
sections were blocked using normal serum provided in the Vectastain kit (Vector
Laboratories, Burlingame, CA) and then incubated with the primary antibody overnight at
4°C. After incubation with biotinylated secondary antibody for an hour at room temperature,
each slide was incubated either with horseradish-peroxidase-conjugated streptavidin
followed by development with diaminobenzidine (Biogenex, San Ramon, CA) or with
alkaline phosphatase-conjugated streptavidin followed by development with Vector Red
(Vector Laboratories). The sections were counterstained with Mayer's hematoxylin. Detailed
information on the selected primary antibodies is shown in Supplementary Table 2.
For the immunohistochemical staining of SNU-2004-GC and SNU-1996-GC, an automated
procedure was applied with a Bond-Max Immunostainer and a Bond polymer Refine
Detection Kit (Leica Microsystems, Germany) according to the manufacturer's
recommendations.
After selecting only cancer tissues in each core, pre-defined staining patterns (membranous
or cytoplasmic) of each protein were considered positive. A staining intensity was scored as
0 (negative), 1 (positive), and 2 (strong positive), and dichotomized into negative (0) and
positive (1-2) for further analysis. If the staining was observed in less than 10% of total
cancer cells within a core, it was considered as negative. Each TMA was scored
Lee et al. Page 4
Gastroenterology. Author manuscript; available in PMC 2011 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
independently by different pathologic specialists without any clinical information
(Vanderbilt-GC and SNUH-TA78 by N.K.T., SNUH-2004-GC by P.H.S., SNU-1996-GC by
K.M.A. and K.W.H.)
Statistical analysis of tissue array staining
The association between protein expression and clinicopathologic variables was evaluated
using the χ2 test. Disease-specific survival curves were calculated by the Kaplan-Meier
method, and the log-rank test was used to evaluate the statistical difference. Any
clinicopathologic variables as well as the expression of certain proteins with a log-rank p-
value less than 0.1 were entered into the multivariate analysis. The Cox proportional hazards
model was used for the multivariate analysis to identify independent prognostic factors for
survival in a combined cohort of a test and a validation set. In addition, prognostic
implications of each protein were evaluated in the subgroup stratified according to tumor
location or Lauren classification in a combined cohort. All statistical analyses were
conducted using the SPSS version 13.0 (Chicago, IL, USA).
Results
Gene expression profile of SPEM and IM compared to normal chief cells
Based on our recent studies indicating that SPEM is derived from chief cells in mice,15,16
we sought to compare the expression profiles for microdissected IM and SPEM compared
with normal chief cells. We identified 858 probes, which were differentially expressed
between chief cells versus IM or SPEM. Among them, 45 probes were significantly up-
regulated in both SPEM and IM, 523 were significantly up-regulated in IM alone, 287 were
significantly down-regulated in IM alone, and 3 were significantly up-regulated in SPEM
alone. No probe was significantly up-regulated in IM and simultaneously significantly
down-regulated in SPEM, and vice versa (Supplementary Table 4). The top 25 genes which
were significantly up-regulated in IM or in SPEM are listed in Table 1.
Identification of markers for gastric metaplastic lineages
To examine the protein expression of selected genes in gastric metaplastic lineages, we
performed immunohistochemical staining in IM, SPEM, and normal gastric fundic mucosa
with more than 20 antibodies. Twelve proteins were expressed in different locations and
distributions in IM, including (1) apical membranous expression in the luminal gland
(ACE2) or in the entire gland (MUC13)21, (2) lateral membranous expression in the entire
gland (CDH17)22 (3) scattered expression at the bases of gland (OLFM4)23, (4) goblet
staining in IM cells in the entire gland (MUC5AC, REG4)24,25, (5) diffuse cytoplasmic
expression in the luminal gland cells (KRT20)26 or in the entire gland (LGALS4, AKR1B10,
FABP1)27, and (6) Paneth cell expression at the bases of glands (LYZ, DEFA5)28. Three
markers (ACE2, LGALS4, AKR1B10) had not been associated with IM previously. In
addition, three proteins (OLFM4, LYZ, DPCR1) were found as novel SPEM markers. Out of
13 proteins described here, eight were completely negative in normal fundic mucosa, but
five including MUC5AC, KRT20, LGALS4, AKR1B10 were expressed in normal foveolar
cells. OLFM4 was expressed strongly in scattered cells at the bases of fundic glands and also
showed variable diffuse staining in parietal cells (Table 2, Fig 1).
Expression profile of metaplastic lineage markers in gastric cancer
To identify the expression profiles in gastric cancer tissues of 13 proteins, which were
expressed in IM or SPEM, we performed immunohistochemical staining in either the
Vanderbilt-GC or SNUH-TA78 tissue arrays. MUC13 showed the highest expression rate in
gastric cancers (50%), followed by OLFM4 (41%), CDH17 (41%), KRT20 (36%), MUC5AC
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(36%), LGALS4 (29%), AKR1B10 (29%), and REG4 (17%). ACE2, FABP1, DPCR1, LYZ,
and DEFA5 were not expressed in any of the gastric cancers (Fig 2). All of the proteins
expressed in gastric cancers showed predominant expression in intestinal-type tumors,
although the difference between intestinal-type and diffuse-type cancers did not reach
statistical significance except for MUC13 and KRT20, both of which showed significantly
higher expression in intestinal-type than in diffuse-type tumors (Table 2).
Clinicopathologic and prognostic significance of MUC13, OLFM4, and CDH17 in gastric
cancer patients
For the proteins which were expressed in more than 40% of gastric cancers (MUC13,
OLFM4, CDH17), we tested the clinicopathologic and prognostic significance of the
expression of these proteins in the SNUH-2004-GC TMA (n=450; test set), and
subsequently validated them in the SNUH-1996-GC TMA (n=502; validation set).
CDH17 was expressed in a membranous pattern in 61.1% and 65.0% of gastric cancers in
the test and the validation set, respectively (Fig 2D). CDH17 expression was significantly
higher in intestinal-type cancers than in diffuse-type cancers. There was no significant
difference in terms of lymphatic or venous invasion. The expression pattern according to
TNM stage was not consistent between the test and the validation set (Table 3). In the test
set, the 5-year survival rate was significantly higher in patients with cancers expressing
CDH17 (p=0.017, Fig 3A). This survival difference was preserved only in patients with
stage I disease (p=0.006, Fig 3C), not in stage II or more (data not shown). Similarly, this
survival difference was preserved only in patients with node-negative disease (p=0.007, Fig
3E), not in cases with node-positive disease (data not shown). These prognostic impacts of
CDH17 were reproduced in the validation set (Fig 3B, D, F).
Two different expression patterns were observed for MUC13: membranous and diffuse
cytoplasmic. The membranous pattern of MUC13 staining was observed in 44.1% of gastric
cancers in the test set and in 44.5% of the validation set, respectively (Fig 2A), and its
expression was significantly higher in intestinal-type tumors and in earlier TNM stage in
both sets. The diffuse cytoplasmic pattern of MUC13 was expressed in 30.7% of the test set
cases and in 25.4% of the validation set (Fig 2B). In contrast with the membranous pattern,
the cytoplasmic expression was significantly higher in advanced TNM stages (Table 3).
Five-year disease-specific survival rate was significantly higher in cases expressing
membranous pattern of MUC13 in the test set (p=0.029, Fig 4A) and in the validation set
(p<0.001, Fig 4B). In contrast, the prognostic impact of cytoplasmic expression of MUC13
showed a tendency towards decreased survival, although it did not reach statistical
significance in either set (Fig. 4C and 4D). These findings support the concept that
redistribution of MUC13 off the membrane is related to poorer patient outcome.
OLFM4 was expressed in a diffuse cytoplasmic pattern in 26.0% of the test set cases and in
27.1% of the validation set (Fig 2C). OLFM4 expression showed a tendency towards higher
expression in intestinal-type cancers than in diffuse-type cancers. There was no significant
difference in relation to TNM stage or lymphatic or venous invasion (Table 3). The
prognostic impact of OLFM4 expression was not observed in the entire gastric cancer
patient cohort. Although 5-year disease-specific survival rate was significantly lower in
OLFM4 positive cases in stage I disease in the test set (p=0.018), this significance was not
observed in the validation set (p=0.889).
Multivariate analysis and Subgroup analysis
When we performed a multivariate analysis of all patients, only TNM classifications were
revealed as an independent prognostic factor for survival (data not shown). However, in the
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case of patients with stage I disease, as with TNM stage and venous invasion, the expression
of CDH17 was also revealed as an independent prognostic factor for disease-specific
survival (Supplementary Table 5). In addition, in the case of patients with node-negative,
curatively resected cancers, as with T-classification, the expression of CDH17 was also an
independent prognostic factor for disease-specific survival (Supplementary Table 5). These
independent prognostic impacts of CDH17 in stage I or in node-negative gastric cancer
patients were observed both in the test set and in the validation set, even when analyzed
separately (data not shown).
In a subgroup analysis according to the tumor location, the expression of CDH17 and the
membranous expression of MUC13 showed a better prognosis only in antral cancers
(p=0.006 and p=0.002, respectively), but not in the non-antral cancers. According to Lauren
classification, the expression of CDH17 showed a better prognosis only in diffuse type
(p=0.014), but not in intestinal type cancers. In contrast, cytoplasmic expression of MUC13
showed worse survival only in intestinal type cancers (p=0.018), not in diffuse type tumors.
Discussion
Perioperative or postoperative chemotherapy is generally recommended for the treatment of
advanced gastric cancer.3,29 However, for stage I gastric cancer, which has a 20∼30% 5-
year recurrence rate, appropriate criteria for adjuvant chemotherapy have not been available.
In contrast, in the early-stage, node-negative breast cancer, a number of prognostic markers
are used in the clinical setting to select candidates for adjuvant treatment.30 The results in
the present investigation suggest that CDH17, an independent prognostic marker for stage I
or node-negative gastric cancer, is a useful biomarker for selection of adjuvant
chemotherapy in early-stage gastric cancer patients, although further large-scale prospective
studies are required.
To identify genes associated with the early neoplastic processes, we have focused the
present investigation on the identification of biomarkers for metaplastic lineages. IM is
established as a possible premalignant lineage for gastric cancer, although many questions
remain regarding its direct involvement in cancer pathogenesis.10,31 In contrast, the role of
SPEM as a preneoplastic process has received attention only recently. Animal studies have
suggested that SPEM originates from transdifferentiation of chief cells in fundic glands, and
can evolve into dysplasia in the presence of a chronic inflammatory process.11,12
Furthermore, investigations in Mongolian gerbils infected with H. pylori and in
amphiregulin knockout mice have supported the concept that SPEM evolves first following
loss of parietal cells, while IM develops from SPEM as a secondary metaplasia.17,18 This
relationship between SPEM and IM is supported by our present cDNA microarray data of
IM and SPEM, where 45 (94%) of 48 probes significantly up-regulated in SPEM were also
significantly up-regulated in IM. Indeed, for a number of these genes, we observed a
progression of increased expression from chief cells to SPEM and from SPEM to IM.
Nevertheless, caution is merited in the interpretation of transcript expression profiles based
on microarray. Thus, we also noted prominent elevations in the expression of TFF1 and
GKN2 transcripts in SPEM and IM. However, while we have observed protein
immunostaining for TFF1 in normal surface cells, in the same sections we saw no staining
of either SPEM or IM (data not shown). It is therefore critical to validate that elevations in
mRNA expression are reflected in changes in protein expression.
Among the genes identified in metaplasia, we successfully documented an independent
prognostic biomarker, CDH17, especially in early-stage gastric cancer. CDH17
(cadherin-17; liver-intestine cadherin) is a structurally unique member of the cadherin
superfamily, and acts as a functional Ca2+-dependent homophilic cell adhesion molecule.32
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In humans, CDH17 is expressed exclusively on the basolateral surface of hepatocytes and
enterocytes, as confirmed in the present study (Fig 1D). After the first report of CDH17 as
an IM marker by Grotzinger et al,22 several investigations have evaluated CDH17
expression in gastric cancer. CDH17 was expressed in 60-78% of gastric cancer tissues with
intestinal-type predominance, similar to our data here.33,34 However, the relationship
between CDH17 expression and cancer stage or patients' survival was inconclusive. Park
and colleagues evaluated the CDH17 expression in more than 200 gastric cancer tissue
samples, and reported that it was highly expressed in earlier TNM stages.35 However, others
reported that its expression was much higher in advanced cancer stages.33,36 As a prognostic
factor, the previously available data were limited, but CDH17 expression showed a tendency
towards an unfavorable indicator for survival.33,36 In our study, the mRNA expression of
CDH17 was increased 156.3-fold in IM and 7.8-fold in SPEM, compared to normal chief
cells. Also, CDH17 was expressed in 61-65% of human gastric cancers with no correlation
with TNM stage. The favorable impact of CDH17 expression on a prognosis of stage I or
node-negative gastric cancer patients, shown in both the test set and the validation set in our
study, may reflect the role of this protein in the maintenance of polarity and normal cell-to-
cell adhesion.
MUC13 (mucin 13) was also revealed as a novel prognostic marker. MUC13 gene encodes a
transmembrane mucin that is specifically expressed in digestive tract tissues.37 Over-
expression of MUC13 was reported previously in several cancers including gastric,
colorectal, and ovarian cancers.21,38,39 Our results showed that two distinct staining patterns
(membranous and cytoplasmic) exist for MUC13 in gastric cancer tissues, a finding similar
to the previous report on colorectal cancer tissues.38 The membranous pattern was expressed
in gastric cancer with intestinal-type histology, an early stage, and a favorable outcome,
while the cytoplasmic pattern correlated with advanced stage. A significant reverse
correlation was observed in membranous and cytoplasmic expression patterns of MUC13 in
our study (R2= -0.173, p<0.001 in Pearson's correlation). The underlying mechanism of this
distinct staining pattern for MUC13 in gastric cancers will require further investigation.
OLFM4 (olfactomedin 4; hGC-1, GW112) is a member of a growing olfactomedin protein
family.40 Some studies indicate that OLFM4 may act as an anti-apoptotic protein that
promotes tumor growth.41 OLFM4 is normally expressed in small intestine, colon, and
prostate, and its mRNA was over-expressed in gastric and colorectal cancers.4,44 Recently,
OLFM4 was identified as a stem cell marker in the human intestine where it is co-expressed
with Lgr5 which was reported as stem cell marker in the pyloric glands, not in the fundic
glands.42,43 Liu et al. first reported the expression of OLFM4 in IM and in 65% of intestinal-
type gastric cancer.23 Recently, Oue et al reported the serum ELISA data of OLFM4 in
gastric cancer patients as well as its prognostic impact on survival.45 In those studies,
OLFM4 was revealed as a favorable prognostic marker in intestinal-type gastric cancer, in
contrast with the present study. Our data indicated that OLFM4 mRNA expression was
increased 309.7-fold in IM and 102.8-fold in SPEM. Also, OLFM4 immunostaining was
detected in 32% of intestinal-type gastric cancers and its prognostic impact was not
consistent between the test set and the validation set. Subgroup analysis according to Lauren
classification also did not show any prognostic impact of OLFM4 in our study. More studies
are needed to validate the clinical implications of OLFM4 in gastric cancer.
In summary, we have identified a number of putative biomarkers for the metaplastic process
in the stomach. CDH17 is an independent prognostic factor in patients with stage I or node-
negative gastric cancer. Evaluation of CDH17 may allow better stratification of stage I
disease patients with poorer prognosis for applying personalized strategies for adjuvant
chemotherapy after curative surgery.
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Refer to Web version on PubMed Central for supplementary material.
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Fig 1. Protein expression of the selected genes in metaplastic lineages in the stomach
See Table 2(A) for detailed information on immunohistochemical staining.
(A-L) Immunohistochemical staining of the selected genes in normal fundus (left, ×50) and
intestinal metaplasia (IM) (right, ×100; insert ×400) (A) ACE2, (B) MUC13, (C) CDH17,
(D) OLFM4, (E) MUC5AC, (F) REG4, (G) KRT20, (H) LGALS4, (I) AKR1B10, (J)
FABP1, (K) LYZ, (L) DEFA5, (M-O) Immunohistochemical staining of the selected genes
in SPEM (M) OLFM4 in SPEM (left, ×50; insert, ×200), (N) LYZ in normal jejunum (left,
×100) and in SPEM (right, ×100; insert, ×400), (O) DPCR1 in normal fundus (left, ×50) and
in SPEM (right, ×100; insert ×400).
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Fig 2. Protein expression of the selected genes in gastric adenocarcinoma
(original magnification ×100; all gastric cancer tissues are intestinal-type, except (B) which
is diffuse-type). (A) MUC13, membranous pattern, (B) MUC13, cytoplasmic pattern, (C)
OLFM4, (D) CDH17, (E) KRT20, (F) MUC5AC, (G) LGALS4, (H) AKR1B10, (I)REG4.
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Fig 3. Disease-specific survival curves of gastric cancer patients according to the expression of
CDH17 in a test set and in a validation set
(A) CDH17 in all stages in the test set), (B) CDH17 in all stages in the validation set, (C)
CDH17 in curatively resected, stage I cases in the test set, (D) CDH17 in curatively
resected, stage I cases in the validation set, (E) CDH17 in curatively resected, node-negative
cases in the test set, (F) CDH17 in curatively resected, node-negative cases in the validation
set.
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Fig 4. Disease-specific survival curves of gastric cancer patients according to the expression of
MUC13 in a test set and in a validation set
(A) membranous pattern of MUC13 in all stages in the test set, (B) membranous pattern of
MUC13 in all stages in the validation set), (C) cytoplasmic pattern of MUC13 in all stages
in the test set, (D) cytoplasmic pattern of MUC13 in all stages in the validation set)
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